At a glance
ClinicalIndex Comparison RecordPhase 2Active· 26 enrolled
Drug / intervention
Lenvatinib Oral Product +1 moredrug
Likely dose
Lenvatinib Oral Product 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted May 3, 2021·Updated Apr 8, 2026
In Brief
A Phase 2 clinical trial evaluating Lenvatinib Oral Product and Pembrolizumab for Merkel Cell Carcinoma and 2 related conditions. Active but no longer recruiting, targeting 26 participants across 1 site.
Detailed Summary
This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMerkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2Active
20222023202420252026
First PostedMay 2021
Enrollment StartMay 2021
Primary CompletionSep 2025
TodayJul 2026
Study CompletionSep 2026
First PostedMay 3, 2021
Enrollment StartMay 28, 2021
Primary CompletionSep 13, 2025
Study CompletionSep 1, 2026
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 5.2 years ago
Interventions
Lenvatinib Oral Productdrug
20mg of Lenvatinib will be taken orally once daily
Pembrolizumabdrug
200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.